secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2026-08-13T20:10:12+00:00
Accession:  0001193125-26-349180
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Q2 net loss $6.3M; cash burn only $319K, Zola July sales $740K
----------------------------------------------------------------------

- Q2 net loss $6.3M ($2.09/share) vs $4.5M loss a year ago; revenue $1.44M, down 1% YoY.
- Cash used in ops only $319K in Q2; cash balance $4.2M after $4M June private placement.
- Zola July sales topped $740K, exceeding $1M through first week of August; Q2 sales flat due to inventory/shipping issues.
- SG&A down $1.0M YoY to all-time low; Q4 2026 launch of 1-liter espresso with pre-launch commitments from two largest customers.
- First half net loss $10.7M ($4.19/share) vs $1.9M loss; includes $5.4M valuation loss on June PIPE and $4.3M unrealized loss on Above Food stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000119312526349180/0001193125-26-349180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000119312526349180/rkda-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer